| dc.contributor.author | Izudi, J. | |
| dc.contributor.author | Bajunirwe, F. | |
| dc.contributor.author | Cattamanchi, A. | |
| dc.date.accessioned | 2023-07-28T13:08:23Z | |
| dc.date.available | 2023-07-28T13:08:23Z | |
| dc.date.issued | 2023 | |
| dc.identifier.citation | Izudi, J., Bajunirwe, F., & Cattamanchi, A. (2023). Increase in rifampicin resistance among people previously treated for TB. Public Health Action, 13(1), 4-6. | en_US |
| dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/3052 | |
| dc.description.abstract | People previously treated for TB are at a higher risk of rifampicin- resistant or multidrug-resistant TB (RR/ MDR-TB). Uganda’s recent RR-TB estimates were not updated, including during the COVID-19 pandemic. Using programmatic data (2012–2021), we report on the distribution and trends in RR-TB among people previously treated for bacteriologically confirmed pulmonary TB (BC-PTB) across six TB clinics in Kampala, Uganda. The RR-TB prevalence between 2012 and 2015 was 0% (95% CI 0–2.3). The prevalence rose significantly in recent years to 7.0% (95% CI 4.4–10.8) between 2016 and 2021 (P < 0.001). RR-TB is increasing among people previously treated for BC-PTB in Kampala; surveillance for
RR-TB should be enhanced. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Public Health Action | en_US |
| dc.subject | Multidrug-resistant tuberculosis | en_US |
| dc.subject | Smear-positive people with TB | en_US |
| dc.subject | Retreatment TB | en_US |
| dc.subject | Uganda | en_US |
| dc.title | Increase in rifampicin resistance among people previously treated for TB | en_US |
| dc.type | Article | en_US |
